Heart rate and cardiovascular risk: What does the BEAUTIFUL study say?
Authors:
F. Kölbel
Published in the journal:
Kardiol Rev Int Med 2008, 10(4): 159-163
Summary
The BEAUTIFUL study has shown that even tho ugh mostly combined with beta blockers, ivabradine has reduced, in a statistically significant way, the need for hospitalisati on and for coronary revascularisati on due to fatal and non‑fatal infarcti on in IHD pati ents with impaired left ventricular functi on and ≥ 70 be ats/ min baseline he art rate. It has also proven that he art rate is a significant prognostic sign in the monitored populati on of pati ents which deserves systematic attenti on. Another important finding is the fact that ivabradine as a drug the effect of which is bo und to the capacity to reduce he art rate can be safely combined with beta blockers which still form part of the basic medicati on for IHD pati ents.
Key words:
ivabradine – heart rate – beta blockers
Zdroje
1. Hradec J. Jak léčit hypertoniky s vyšší srdeční frekvencí? In: Arteri ální hypertenze. Praha: Galén 2007: 115– 123.
2. Benetos A, Rudnichi A, Thomas F et al. Influence of he art rate on mortality in a French populati on: role of age, gender, and blo od pressure. Hypertensi on 1999; 33: 44– 52.
3. Seccarecci a F, Pannozzo F, Dima F et al. He art rate as a predictor of mortality: the MATISS project. Am J Public He alth 2001; 91: 1258– 1263.
4. Benetos A, Thomas F, Be an K et al. Resting he art rate in older pe ople: a predictor of survival to age 85. J Am Geri atr Soc 2003; 51: 284– 285.
5. Di az A, Bo urassa MG, Guertin MC et al. Long‑term prognostic value of resting he art rate in pati ents with suspected or proven coronary artery dise ase. Eur He art J 2005; 26: 967– 974.
6. Kolloch R, Legler UF, Champi on A et al. Impact of resting he art rate on o utcomes in hypertensive pati ents with coronary artery dise ase: findings from the INternati onal VErapamil SR/ Trandolapril Study ( INVEST). Eur He art J 2008; 29: 1327– 1334.
7. Jespersen CM, Fischer HJ. The Danish Verapamil Infarcti on Tri al II. Am J Cardi ol 1990; 66: 779– 785.
8. Freemantle N, Cleland J, Yo ung P et al. Beta‑blockade after myocardi al infarcti on: systematic revi ew and meta regressi on analysis. BMJ 1999; 318: 1730– 1737.
9. Task Force Members, López- Sendó J, Swedberg K, McMurray J et al. Expert consensus document on b‑adrenergic receptor blockers. The Task Force on Beta‑Blockers of the Europe an Soci ety of Cardi ology. Expert consensus document on b‑adrenergic receptor blockers. Eur He art J 2004; 25: 1341– 1362.
10. Hunt SA, Abraham WT, Chin MH et al. ACC/ AHA 2005 guideline update for the di agnosis and management of chronic he art failure in the adult: summary article. J Am Coll Cardi ol 2005; 46: 1116– 1143.
11. Swedberg K, Cleland J, Dargi e H et al. Task Force for the Di agnosis and Tre atment of Chronic He art Failure of the Europe an Soci ety of Cardi ology: Guidelines for the di agnosis and tre atment of chronic he art failure: executive summary (update 2005). Eur He art J 2005; 26: 1115– 1140.
12. Smith SC Jr, Allen J, Blair SN et al. AHA/ ACC guidelines for secondary preventi on for pati ents with coronary and other atherosclerotic vascular dise ase: endorsed by the Nati onal He art, Lung, and Blo od Institute. 2006 update. Circulati on 2006; 113: 2363– 2372.
13. Kjekshus JK. Importance of he art rate in determining beta‑blocker efficacy in acute and long‑term acute myocardi al infarcti on interventi on tri als. Am J Cardi ol 1986; 57: 43F– 49F.
14. Rosen MR, Camm AJ, Steg PG et al. If inhibiti on: a new strategy to improve the management of coronary pati ents. Eur He art J Suppl 2006; 8: D3– D15.
15. Fox K, Ferrari R, Tendera M et al. Rati onale and design of a randomized, do uble- blind, placebo- controlled tri al of ivabradine in pati ents with stable coronary artery dise ase and left ventricular systolic dysfuncti on: the morBidity- mortality EvAlUaTi on of the If inhibitor ivabradine in pati ents with coronary dise ase and leFt ventricULar dysfuncti on (BEAUTIFUL) Study. Am He art J 2006; 152: 860– 866.
16. BEAUTIFUL Study Gro up. The BEAUTIFUL Study: Randomized Tri al of Ivabradine in Pati ents with Stable Coronary Artery Dise ase and Left Ventricular Systolic Dysfuncti on – Baseline Characteristics of the Study Populati on. Cardi ology 2008; 110: 271– 282.
17. Fox K, Ford I, Steg PG et al. Ivabradine for pati ents with stable coronary artery dise ase and lef- ventricular systolic dysfuncti on (BEAUTIFUL): a randomised, do uble- blind, placebo- controlled tri al. Lancet 2008: 372: 807– 816.
18. Hradec J, Sachová M. Jak se v ČR mění klinický obraz a léčba stabilní anginy pectoris. CorVasa 2007; 49: 293– 302.
19. Fox K, Ford I, Steg PG et al. He art rate as a prognostic risk factor in pati ents with coronary artery dise ase and left- ventricular systolic dysfuncti on (BEAUTIFUL): a subgro up analysis of a randomized controlled tri al. Lancet 2008: 372: 817– 821.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2008 Číslo 4
Najčítanejšie v tomto čísle
- Hypertensive disease and heart rate
- Abdominal obesity – an epidemic of the 21st century
- Thrombolytic therapy of cerebral infarction
- Central and peripheral blo od pressure and their control by tre atment